# Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

> **NCT05266729** · PHASE2 · COMPLETED · sponsor: **AMIpharm Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Moderate or Severe Submental Fullness

## Interventions

- **DRUG:** Polyene Phosphatidylcholine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05266729
- **Lead sponsor:** AMIpharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-02
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-02-20
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266729, "Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05266729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*